- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05436223
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for R/R B-NHL.
Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Xuedong Sun, M.D.
- Phone Number: +8615811287219
- Email: sunxuedong@dashengbio.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Zhongshan Hospital, Fudan University
-
Contact:
- Peng Liu, M.D. & Ph.D.
- Phone Number: 0086-021-60267405
- Email: liu.peng@zs-hospital.sh.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:Subjects with relapsed/refractory B-cell non-Hodgkin's lymphoma
- Age≥18 years old,gender is not limited;
- Expected survival > 12 weeks;
- ECOG score 0-2;
- B-cell non-Hodgkin's lymphoma confirmed by cytology or histopathology according to the 2016 World Health Organization (WHO) classification and diagnostic criteria, including: diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed filter Alveolar lymphoma (TFL) and high-grade B-cell lymphoma (HGBCL);
Pathology demonstrated that B-cell non-Hodgkin's lymphoma and who meet one of the following conditions:
- Relapsed and refractory B-cell non-Hodgkin's lymphoma, after standard first-line treatment and at least 2 courses of second-line treatment without remission and relapse (the previous use of CD20-targeted drugs and anthracyclines were needed);
- Relapse of B-cell non-Hodgkin lymphoma after stem cell transplantation, regardless of previous treatments.
- The venous access required for collection can be established and leukepheresis can be carried according to the judgement of investigators, satisfying hemoglobin≥80g/L, neutrophils ≥1.0×10^9/L, platelets ≥75×10^9 / L;
- According to the Lugano 2014 criteria, there should be at least one measurable tumor lesion;
Liver, kidney and cardiopulmonary functions meet the following requirements:
- Serum creatinine≤1.5×ULN or creatinine clearance rate≥50mL/min (GockcroftGault formula);
- Cardiac ejection fraction >50%, no clinically significant pericardial effusion detected, no clinically significant pleural effusion detected;
- Baseline blood oxygen saturation>92%;
- Total bilirubin≤1.5×ULN(Gilbert syndrome≤5×ULN);
- ALT and AST≤3×ULN (AST and ALT ≤5×ULN in patients with liver metastases);
- Able to understand and sign the Informed Consent Document.
Exclusion Criteria:Any one of the following conditions cannot be selected as a subject:
- Malignant tumors other than diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL), and high-grade B-cell lymphoma (HGBCL) within 5 years prior to screening, in addition to adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical resection, ductal carcinoma in situ after radical resection and thyroid cancer after radical resection ;
- Subjects with positive Hepatitis B surface antigen(HBsAg) or Hepatitis B core antibody (HBcAb) and positive peripheral blood hepatitis B virus (HBV) DNA titers (higher than the upper limit of the normal range of the investigative site); Hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive; Human Immunodeficiency Viral (HIV) antibody positive; syphilis positive;
- Any uncontrolled systemic diseases, including but not limited to active infection (except for localized infection), uncontrolled angina, cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York heart association (NYHA) classification ≥ III), need drug therapy of severe arrhythmia, liver, kidney, or metabolic disease;
- Any other uncontrolled active disease that precludes participation in the trial;
- Any circumstances that the investigator believes will compromise the safety of the subject or interfere with the purpose of the study;
- Pregnant or lactating woman, or planned pregnancy during treatment or within 1 year after treatment, or male subject whose partner plans to have a pregnancy within 1 year after cell transfusion;
- Active or uncontrollable infection requiring systemic therapy within 14 days prior to enrollment (except uncomplicated urinary tract infection or upper respiratory tract infection);
- Subjects who were receiving systemic steroid treatment within 14 days before enrollment and who were judged by the investigator to require long-term use of systemic steroid therapy during treatment (except inhalation or topical use); or subjects who received any systemic anti-tumor therapy ( except for local anti-tumor therapy) ;
- Subjects who have received CAR-T treatment or other gene-modified cell therapy before enrollment;
- Patients with symptoms of central nervous system or brain metastasis or have received treatment for central nervous system or brain metastasis (radiotherapy, surgery or other treatment) within 3 months before enrollment;
- Subjects who have a disease that affects the signing of written informed consent or who are unable to comply with research procedures; or who are unwilling or unable to comply with research requirements;
- Subjects who are considered unsuitable to participate in this trial by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Human CD19 Targeted T Cells Injection
Single administration:2.0×10^6
CAR+T/kg
|
A single dose of predetermined level CAR-positive T cells will be infused.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR) at 3 months post infusion
Time Frame: 3 months post infusion
|
ORR is defined as proportion of subjects who achieved Partial remission(PR) or better at 3 months (D90±7) post infusion as assessed by an independent review committee (IRC) based on Lugano 2014 criteria.
|
3 months post infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of remission (DOR) after administration
Time Frame: 2 years post infusion
|
DOR refers to the time from the first assessment of complete response or partial response to the first assessment of disease progression or death from any cause.
|
2 years post infusion
|
Progression-free Survival (PFS) after administration
Time Frame: 2 years post infusion
|
PFS refers to the time from the start of cell infusion to the first assessment of tumor progression or death from any cause.
|
2 years post infusion
|
Overall Survival (OS) after administration
Time Frame: 2 years post infusion
|
OS refers to the time from cell infusion to death due to any cause.
|
2 years post infusion
|
Disease control rate (DCR)
Time Frame: 2 years post infusion
|
The best overall response is the ratio of partial response(PR) or complete response(CR) or stable disease(SD) patients to the total number of cases.
|
2 years post infusion
|
Safety evaluation
Time Frame: 2 years post infusion
|
The occurrence and outcome of adverse events evaluated by physical examination, laboratory examination, electrocardiogram, imaging scan, etc.
|
2 years post infusion
|
Pharmacokinetic (PK) parameters: Maximum CAR level inperipheral blood
Time Frame: 2 years post infusion
|
The highest concentration of Human CD19 Targeted T Cells Injection amplified in peripheral blood after infusion (Cmax) .
|
2 years post infusion
|
Pharmacokinetics(PK) parameters: Time to peak CAR level in blood (Tmax)
Time Frame: 2 years post infusion
|
The time to reach the highest concentration of Human CD19 Targeted T Cells Injection in peripheral blood after infusion (Tmax) .
|
2 years post infusion
|
Pharmacokinetics(PK) parameters: 28-day Area under the curve of the CAR level in blood(AUC0-28)
Time Frame: 2 years post infusion
|
The 28-day area under the curve of Human CD19 Targeted T Cells Injection in peripheral blood after infusion(AUC0-28d).
|
2 years post infusion
|
Pharmacodynamic (PD) parameters
Time Frame: 2 years post infusion
|
The clearance degree of CD19 positive B cells in peripheral blood at respective time point.
|
2 years post infusion
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HRAIN01-NHL01-Ⅱ
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on B-cell Non-Hodgkin's Lymphoma
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
Hoffmann-La RocheCompletedDiffuse Large B-Cell Lymphoma, Non-Hodgkin's LymphomaHong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Non-Hodgkin's Lymphoma | Intermediate Grade B-Cell Non-Hodgkin's LymphomaUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
Debiopharm International SACompletedDiffuse Large B-Cell Lymphoma | B-cell Non-Hodgkin's LymphomaUnited States, Czechia, Belgium, Hungary, Ukraine, Bulgaria, Italy, Poland, Switzerland
-
Eden BioCell Ltd.National Taiwan University HospitalTerminatedFollicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryTaiwan
-
Peking UniversityPeking University Cancer Hospital & InstituteRecruitingB Cell Non-Hodgkin's LymphomaChina
-
Peking UniversityUnknownB-cell Non-Hodgkin's Lymphoma
-
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Not yet recruitingB-cell Non-Hodgkin's Lymphoma
-
Second Affiliated Hospital, School of Medicine,...Zhejiang Ruijiamei Biotechnologies, Co., Ltd.RecruitingB-cell Non-Hodgkin's LymphomaChina
Clinical Trials on Human CD19Targeted T Cells Injection
-
Hrain Biotechnology Co., Ltd.First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng... and other collaboratorsRecruiting
-
Hrain Biotechnology Co., Ltd.Shanghai Zhongshan HospitalRecruitingFollicular Lymphoma | Diffuse Large B-cell Lymphoma | CD19-positiveChina
-
Hrain Biotechnology Co., Ltd.Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineRecruitingAcute Lymphoblastic Leukemia | CD19-positiveChina
-
Hrain Biotechnology Co., Ltd.First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng...Recruiting
-
Hrain Biotechnology Co., Ltd.Ruijin HospitalNot yet recruitingAcute Lymphoblastic LeukemiaChina
-
Hrain Biotechnology Co., Ltd.Second Affiliated Hospital of Nanchang UniversityRecruitingCentral Nervous System LymphomaChina
-
Hrain Biotechnology Co., Ltd.Second Affiliated Hospital of Nanchang UniversityRecruitingB-cell Acute Lymphoblastic LeukemiaChina
-
Ruijin HospitalShanghai Essight Bio Co.,LtdRecruiting
-
Yan'an Affiliated Hospital of Kunming Medical UniversityKAEDIUnknownB Cell Lymphoma | B-cell Acute Lymphoblastic LeukemiaChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingMultiple Myeloma | New Diagnosis TumorChina